<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02791620</url>
  </required_header>
  <id_info>
    <org_study_id>256/59</org_study_id>
    <nct_id>NCT02791620</nct_id>
  </id_info>
  <brief_title>The Efficacy of Nanofractional Radiofrequency Device in Arm Rejuvenation and Tightening : a Pilot Study</brief_title>
  <official_title>The Efficacy of Nanofractional Radiofrequency Device in Arm Rejuvenation and Tightening : a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Venus Concept</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate arm rejuvenation and tightening with a
      nanofractional radiofrequency device, Venus viva, Venus concept, Toronto Canada. We recruit
      20 subjects. All 20 subjects are treated with 3 sessions, 1 month interval with a nano
      fractional radiofrequency device on the inner upper arm. We evaluate skin tightening using
      %improvement of treated surface areas and skin elasticity using Dermalab the result at 3
      months after the last treatment and clinical improvements evaluated by two board certified
      dermatologist (using compared photos between before treatment and 3 months after the last
      treatment).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of arm rejuvenation and tightening</measure>
    <time_frame>12 weeks after the last treatment</time_frame>
    <description>Determined by changing of the treated surface area (calculated from four-fixed tattoo points on the inner arm) surface area = length x width cm2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changing of skin laxity and elasticity</measure>
    <time_frame>12 weeks after the last treatment</time_frame>
    <description>Evaluated by skin's viscoelastic properties using Dermalab, Courage Khazaka Electronic GmbH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing of skin wrinkles and laxity using photographs of subjects' baselines and 12 weeks after the last treatment by two independent board certified dermatologists</measure>
    <time_frame>12 weeks after the last treatment</time_frame>
    <description>Determined by five point scale. (1) excellent improvement (&gt;75%), (2) good improvement (50-75%), (3) fair improvement (25-50%), (4) some improvement (10-25%) and (5) little or no improvement (0-10%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate perceptions of treatment with a nano-fractional radiofrequency device</measure>
    <time_frame>12 weeks after the last treatment</time_frame>
    <description>using five-point scale Five point scale evaluation: (1) excellent improvement (&gt;75%), (2) good improvement (50-75%), (3) fair improvement (25-50%), (4) some improvement (10-25%) and (5) little or no improvement (0-10%)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Skin Tightening and Rejuvenation</condition>
  <arm_group>
    <arm_group_label>A nanofractional radiofrequency device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>a nanofractional radiofrequency device</intervention_name>
    <description>A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.</description>
    <arm_group_label>A nanofractional radiofrequency device</arm_group_label>
    <other_name>Venus Viva, Venus concept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Healthy female or male subjects, at least 30-60 years old of age 2. Subject who has
             BMI 18.50- 25 kg/m2 (as picture criteria above) 3. Subject has clinically evident
             moderate skin laxity with or without wrinkle on the upper arm 4. Subject has read and
             signed a written informed consent form.

        Exclusion Criteria:

        - 1. Patient with weight loss &gt; 15% 2. Pregnancy or Lactation 3. History of pacemaker,
        defibrillator 4. History of laser resurfacing, prior radiofrequency, ultrasound or focused
        ultrasound on treatment areas within 1 year on the treatment area 5. History of Heat
        sensitivity, collagen vascular disorder disease including morphea, scleroderma, heat
        contact urticaria 6. History of medical illness that primary investigator thinks could
        interfere or influence the wound healing process 7. History of abnormal scars (keloid,
        hypertrophic scars) 8. History of skin cancer, radiation therapy or metal implants on
        treatment areas 9. Active local or systemic infection on treatment areas 10. Any other
        conditions that would, in the professional opinion of the investigator, potentially affect
        the subject's response or the integrity of the data or would pose an unacceptable risk to
        the subject.

        11. Subject is unable or unwilling to comply with the study requirements. 12. Subject is
        currently enrolled in a clinical study of any other unapproved investigational drug or
        device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Dermatology, Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marisa Pongprutthipan, MD</last_name>
      <phone>022564253</phone>
      <email>Dr_marisa@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Chanika Witoonchart, MD</last_name>
      <phone>022564253</phone>
      <email>C.kulapatrapa@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Elsaie ML, Choudhary S, Leiva A, Nouri K. Nonablative radiofrequency for skin rejuvenation. Dermatol Surg. 2010 May;36(5):577-89. doi: 10.1111/j.1524-4725.2010.01510.x. Epub 2010 Apr 2. Review.</citation>
    <PMID>20384760</PMID>
  </reference>
  <reference>
    <citation>Hruza G, Taub AF, Collier SL, Mulholland SR. Skin rejuvenation and wrinkle reduction using a fractional radiofrequency system. J Drugs Dermatol. 2009 Mar;8(3):259-65.</citation>
    <PMID>19271373</PMID>
  </reference>
  <reference>
    <citation>Hantash BM, Ubeid AA, Chang H, Kafi R, Renton B. Bipolar fractional radiofrequency treatment induces neoelastogenesis and neocollagenesis. Lasers Surg Med. 2009 Jan;41(1):1-9. doi: 10.1002/lsm.20731.</citation>
    <PMID>19143021</PMID>
  </reference>
  <reference>
    <citation>Sukal SA, Geronemus RG. Thermage: the nonablative radiofrequency for rejuvenation. Clin Dermatol. 2008 Nov-Dec;26(6):602-7. doi: 10.1016/j.clindermatol.2007.09.007.</citation>
    <PMID>18940540</PMID>
  </reference>
  <reference>
    <citation>Desai S. Nonsurgical Lifting and Tightening. Evidence-Based Procedural Dermatology: Springer; 2012. p. 287-300.</citation>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2016</study_first_submitted>
  <study_first_submitted_qc>June 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2016</study_first_posted>
  <last_update_submitted>June 1, 2016</last_update_submitted>
  <last_update_submitted_qc>June 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

